	Application No.	Applicant(s)
Notice of Allowability	09/856,415	TALTON ET AL.
	Examiner	Art Unit
	Humera N. Sheikh	1615
The MAILING DATE of this communication apperation All daims being allowable, PROSECUTION ON THE MERITS IS therewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIPORT OF THE OFFICE OF UPON PETENT OF THE OFFICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIPORT OF THE OFFICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIPORT OF THE OFFICE OFFICE OF THE OFFICE OFFICE OFFICE OF THE OFFICE OFFICE OF THE OFFICE OFFI	tars on the cover sheet with the county (OR REMAINS) CLOSED in this applied or other appropriate communication GHTS. This application is subject to and MPEP 1308. The communication is subject to an arrangement of the communication is subject to an arrangement of the communication is subject to an arrangement of the communication is subject to a communication in the communication is subject to a communication in the communication is subject to a communication in the communication in the communication is subject to a communication in the communication in this application is subject to a communication in this application is subject to a communication in the communication in this application is subject to a communication in the communication in the communication is subject to a communication in the communication is subject to a communication in the communication in the communication is subject to a communication in the communication in the communication is subject to a communication in the communication i	prrespondence address plication. If not included a will be mailed in due course. THIS b withdrawal from issue at the initiative
	cuments have been received in this	national stage application from the
 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	6. ☑ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amenda 8. ☑ Examiner's Stateme 9. □ Other	ie <u>6/20/05</u> .

DETAILED ACTION

Status of the Application

Receipt of the Amendment after Final Rejection and Applicant's Arguments/Remarks,

both filed 06/13/05 is acknowledged.

Claims 28, 30-44 and 48-67 are pending. Claim 57 has been amended via Examiner's

Amendment. Claim 29 has been cancelled. Claims 28, 30-44 and 48-67 are allowed.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Neil R. Jetter on June 20, 2005.

The application has been amended as follows:

In the Claims:

In Claim 57, line 2, the phrase 'in accordance with claim 28' has been deleted and

replaced with the phrase 'comprising a plurality of coated drug particles, each of said coated

drug particles having an average particle size of less than 50 µm in diameter, the surface of said

particles comprising at least a first coating layer of biodegradable and bio-compatible material, said coating layer being a continuous and non-porous layer, wherein an average thickness of said coating layer is between 1 and 500 nm, wherein said coating layer is exclusive of said drug provided by said drug particles.'

Allowable Subject Matter

Claims 28, 30-44 and 48-67 are allowed.

The following is an examiner's statement of reasons for allowance:

The primary reasons for allowance are that the prior art (Moro et al. US 5,223,244; Green et al. US 5,976,577; Sakon et al. US 5,972,388; Hanes et al. US 5,855,913; Bucks et al. US 6,277,364) does not disclose nor fairly suggest a medicament comprising coated drug particles, each of the said coated drug particles having an average particle size of less than 50 um in diameter, the surface of said particles comprising a first coating layer of biodegradable and biocompatible material, wherein the coating layer is a continuous, non-porous layer, having an average thickness of between 1 and 500 nm, and wherein the coating layer is exclusive of said drug provided by said drug particles. In the Final Office Action filed 06/03/05, the Examiner objected to claim 29, which specifically recites that the "coating layer is exclusive of said drug provided by said drug particles" and indicated that claim 29 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicants have adopted the Examiner's suggestion and have incorporated the claim limitations of allowable claim 29 into independent claim 28, canceling claim 29. Additionally, Applicants

have incorporated the allowable claim limitations of claim 29 into independent method claim 66, to place the application in condition for allowance. The instant invention provides for an improvement over prior art formulations because it allows for control of the coating layer and in particular, control of the thickness and uniformity of the coating layer and offers encapsulation that can be partial or complete. Accordingly, since the prior art fails to disclose or suggest the claimed medicament of the instant invention, the instant invention is rendered non-obvious and patentable over the cited art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (571) 272-0604. The examiner can normally be reached on Monday through Friday from 8:00A.M. to 5:30P.M., alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Application/Control Number: 09/856,415

Art Unit: 1615

Page 5

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have any questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

H. N. Sheikh

Patent Examiner

Art Unit 1615

June 20, 2005

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY SENTER 1600